NCT04169074 2026-01-14
Immune Modulation by Abemaciclib in Head and Neck Squamous Cell Carcinoma (HNSCC). (AIM Trial)
University of Arizona
Phase 2 Terminated
University of Arizona
Sanofi
Mayo Clinic
Eli Lilly and Company
University of Texas Southwestern Medical Center
University of Milano Bicocca
Eli Lilly and Company